Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Magnolia Oil & Gas Corporation Class A Common Stock (MGY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Magnolia Oil & Gas Corporation Class A Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.13 (market cap $6.57B), while Magnolia Oil & Gas Corporation Class A Common Stock trades at $24.9 (market cap $6.76B). The key difference: Iovance Biotherapeutics Inc. Common Stock and Magnolia Oil & Gas Corporation Class A Common Stock are close in size by market cap, and Magnolia Oil & Gas Corporation Class A Common Stock pays a 2.63% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 1 Days and Magnolia Oil & Gas Corporation Class A Common Stock for 0 Days on average.
| IOVA | MGY | |
|---|---|---|
Market Cap | $6.57B | $6.76B |
Volume | 11,838,721 | 2,815,157 |
Sector | Health | Energy |
52-Week High | $14.82 | $32.36 |
52-Week Low | $1.81 | $21.24 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $6.50B | $6.88B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
Magnolia Oil & Gas (MGY) trades at $25.11, up 2.66% with neutral technical signals. The company demonstrates strong fundamentals with a P/E of 10.97, net income margin of 28.77%, and consistent earnings beats. Recent WildFire Energy acquisition positions MGY for production doubling and significant free cash flow growth, with 2027 FCF projected over $1 billion. Analyst consensus remains strongly bullish with 66.7% buy ratings and $33.78 price target.
MGY presents compelling value with attractive valuation multiples and robust profitability metrics. The WildFire acquisition accelerates growth but introduces integration execution risk. Current price offers 35% upside to consensus target, though oil price volatility and operational execution remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Magnolia Oil & Gas Corporation Class A Common Stock
Magnolia Oil & Gas Corporation is an independent oil and gas exploration and production company operating in the Eagle Ford Shale and Austin Chalk formations of South Texas.
Read more on MGY →
